Tage Honore sold $241k of VNDA
director at Vanda Pharmaceuticals Inc.. 30,000 shares at an average of $8.03, traded Feb 23, 2026, filed Feb 24, 2026.
Score components
- +15RoleDirector
- +13Trade size$241k at market
- +5Share of holdings soldSold 24% of holdings
- +15Cluster6 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -12.9%, 3m -23.9%, 6m -33.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-067185, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 23, 2026 | SOpen-market sale Common Stock | -30,000 | $8.03 | $241k | 93,469 | Feb 24, 2026 |
Related signals
Other insiders at Vanda Pharmaceuticals Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | Vanda Pharmaceuticals Inc. | Gunther Birznieks SVP, Business Development | $351k 42,431 shares | -8% | |
| 52Moderate | Vanda Pharmaceuticals Inc. | Kevin Patrick Moran SVP, CFO & Treasurer | $351k 42,442 shares | -9% | |
| 65Notable | Vanda Pharmaceuticals Inc. | Mihael Hristos Polymeropoulos President and CEO | $1.3M 156,235 shares | -5% | |
| 50Moderate | Vanda Pharmaceuticals Inc. | Timothy Williams SVP & General Counsel | $351k 42,434 shares | -10% | |
| 43Moderate | Vanda Pharmaceuticals Inc. | Joakim Wijkstrom SVP, Chief Marketing Officer | $255k 30,800 shares | -8% | |
| 45Moderate | VNDAbuy Vanda Pharmaceuticals Inc. | Mihael Hristos Polymeropoulos President and CEO | $42k 10,000 shares | +0% | |
| 20Weak | VNDAsell Vanda Pharmaceuticals Inc. | Stephen Ray Mitchell director | $32k 7,000 shares | -7% | |
| 35Weak | VNDAbuy Vanda Pharmaceuticals Inc. | Mihael Hristos Polymeropoulos President and CEO | $44k 10,000 shares | +0% | |
| 43Moderate | VNDAbuy Vanda Pharmaceuticals Inc. | Mihael Hristos Polymeropoulos President and CEO | $84k 20,000 shares | +1% | |
| 25Weak | VNDAsell Vanda Pharmaceuticals Inc. | Stephen Ray Mitchell director | $26k 5,000 shares | -10% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.